PM8002/BNT327 Combo Improves Efficacy and Safety in Metastatic TNBC
Data from a phase 1b/2 study show a 78.6% ORR in patients with metastatic triple-negative breast cancer treated with PM8002/BNT327 plus nab-paclitaxel.
Reducing Post-Mastectomy Disparities in Breast Cancer Minority Populations
A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.
Osimertinib With or Without Chemo is Top Choice for Frontline NSCLC
The NCCN guidelines have stated that osimertinib is the preferred category 1 treatment for patients with EGFR-mutated NSCLC discovered before the first line of therapy.
Highlighting Advocacy Impacts on Funding for Kidney Cancer Research
Two oncologists discuss the impact of advocacy in kidney cancer research, highlighting collaboration between researchers, advocates, and physicians.
Obe-cel Elicits Durable Responses in Relapsed/Refractory B-Cell ALL
In the phase 1b/2 FELIX study, obecabtagene autoleucel was associated with low incidence of grade 3 or higher immune-related toxicity.
ctDNA Positivity More Frequent Less Than 6 Months from Treatment in TNBC
The phase 3 ZEST trial discovered that, with low ctDNA at baseline, the recurrence-free interval is longer for patients with triple-negative breast cancer.
